insights_auto
Why is GRF up 2,30%?
Dive Deeperchevron_right
GRF:BME
Grifols SA Class A
9,88 €
arrow_upward
+2,30%(+0,22) 1D
6-окт., 17:36:00 GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GRF...
Open
9,75 €
High
10,03 €
Low
9,70 €
Mkt. cap
5,73 млд
Avg. vol.
1,14 млн
Volume
2,06 млн
Dividend
2,35%
Quarterly dividend
0,06 €
Ex-dividend date
2026-ж., 30-июн.
P/E ratio
14,86
52-wk high
12,51 €
52-wk low
8,43 €
EPS
0,67 €
Shares outstanding
426,13 млн
No. of employees
25 миң
Open
9,75 €
High
10,03 €
Low
9,70 €
Mkt. cap
5,73 млд
Avg. vol.
1,14 млн
Volume
2,06 млн
Dividend
2,35%
Quarterly dividend
0,06 €
Ex-dividend date
2026-ж., 30-июн.
P/E ratio
14,86
52-wk high
12,51 €
52-wk low
8,43 €
EPS
0,67 €
Shares outstanding
426,13 млн
No. of employees
25 миң
News stories
From web sources and news partners
AD HOC NEWS
·
1 күн мурун
Grifols stock gains as H1 profit rises 28.7 percent
The New York Times
·
1 ай мурун
After 2 Plasma Donor Deaths, Company Pauses Clinics in Canada
Profile
Grifols, S.A. is a global healthcare company and leading producer of plasma-derived medicines founded in Barcelona, Catalonia, Spain, in 1909. With a workforce of over 23,800 employees, Grifols serves more than 110 countries and regions and maintains a direct presence in over 30.
Principally a producer of blood plasma–based products and other biopharmaceuticals, the company also operates in transfusion medicine, supplying devices, instruments and reagents for clinical testing laboratories, as well as clinical diagnostic technologies. Furthermore, it provides biological supplies for life-science research, clinical trials and the manufacturing of pharmaceutical and diagnostic products. It has a portfolio on four therapeutic areas: immunology, infectious diseases, pulmonology and critical care. Wikipedia
About Grifols SA Class A